Healthcare innovation set to drive sustainable returns

Despite the uncertainty on the political front and the macroeconomic unknowns, the biotech sector's fundamentals have remained solid.

Partner insight BB Biotech AG, one of the largest biotech investors in Europe, has weathered the past eighteen months and all the volatility comparatively well. This positive performance has continued into 2017. The total return for BB Biotech's share price in Q1 this year was 7.4% in CHF and 7.0% in EUR. The portfolio showed an overall gain of 12.6% in CHF, 12.3% in EUR and 14.5% in USD. "Regulatory approvals of biotech drugs, successful clinical trials involving new treatment approaches and ongoing takeover activity suggest that the biotech industry will continue to deliver double-d...